Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: EyeDrMike who wrote (13476)	8/17/1998 11:36:00 AM
From: VLAD	Respond to of 23519

mike, Keeping your last post in mind.....it would seem to me that if Astra and JNJ know that MUSE/Alibra will be a real player in the ED market they would be best off to offer Vivus a steep premium NOW for a buy out. Today an offer of let's say 15-20 may seem steep but if the product sells and Vivus can show some strong numbers then in 1999 15-20 may seem cheap. IMO Vivus will not sell even if offered 15-20 since they feel that the stock will be worth a lot more than 15-20 2 to 3 years from now.